RxDoctor Payments Data

Penny Orr

Optometrist · Naples, FLNPI 1477644128

Payments from drug & device makers

$1,868in general payments, 2019–2025

Across 67 payments — averaging $27.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$427
  • Johnson & Johnson Vision Care, Inc.$381
  • Coopervision Inc.$286
  • Johnson & Johnson Surgical Vision, Inc.$272
  • Dompe US, Inc.$124
  • Sun Pharmaceutical Industries Inc.$118
  • plus $260 from 6 others

What the payments were for

  • Food & beverage$1,868100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,868 in reported general payments places this provider in the 65th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$184,510
Medicare patients
870
Services billed
1,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$63,003
XiidraLifitegrast15$24,671
LumiganBimatoprost14$8,209
Travatan ZTravoprost12$7,186
Cyclosporine19$7,079
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$3,886
RocklatanNetarsudil Mesylat/Latanoprost11$3,759
Loteprednol Etabonate21$3,084
Brimonidine Tartrate53$3,047
Latanoprost209$2,641
Tobramycin-DexamethasoneTobramycin/Dexamethasone34$1,352
Timolol Maleate78$1,280
Prednisolone Acetate38$1,209
ErythromycinErythromycin Base108$1,112
MoxifloxacinMoxifloxacin Hcl52$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$92$71,21258 claims
Bausch & Lomb Americas Inc.Xiidra$38$24,67115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →